TY - JOUR
T1 - Circulating tumor DNA alterations in patients with metastatic castration-resistant prostate cancer
AU - Sonpavde, Guru
AU - Agarwal, Neeraj
AU - Pond, Gregory Russell
AU - Nagy, Rebecca J.
AU - Nussenzveig, Roberto H.
AU - Hahn, Andrew W.
AU - Sartor, Oliver
AU - Gourdin, Theodore Stewart
AU - Nandagopal, Lakshminarayanan
AU - Ledet, Elisa M.
AU - Naik, Gurudatta
AU - Armstrong, Andrew J.
AU - Wang, Jue
AU - Bilen, Mehmet Asim
AU - Gupta, Shilpa
AU - Grivas, Petros
AU - Pal, Sumanta K.
AU - Lanman, Richard B.
AU - Talasaz, Amir Ali
AU - Lilly, Michael B.
N1 - Publisher Copyright:
© 2019 American Cancer Society
PY - 2019/5/1
Y1 - 2019/5/1
N2 - Background: Because cell-free DNA (cfDNA) analysis facilitates the noninvasive genomic profiling of metastatic castration-resistant prostate cancer (mCRPC), the authors evaluated the association between cfDNA alterations and outcomes and evolution with therapy. Methods: Patients with mCRPC underwent cfDNA genomic profiling using Guardant360, which examines major cancer-associated genes. Clinical factors, therapy information, failure-free survival, and overall survival (OS) were obtained for select patients. The association between genomic alterations and outcomes was investigated. Results: Of 514 men with mCRPC, 482 (94%) had ≥1 circulating tumor DNA (ctDNA) alteration. The most common recurrent somatic mutations were in TP53 (36%), androgen receptor (AR) (22%), adenomatous polyposis coli (APC) (10%), neurofibromin 1 (NF1) (9%), epidermal growth factor receptor (EGFR), catenin beta-1 (CTNNB1), and AT-rich interactive domain-containing protein 1A (ARID1A) (6% each); and BRCA1, BRCA2, and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) (5% each) The most common genes with increased copy numbers were AR (30%), MYC (20%), and BRAF (18%). Clinical outcomes were available for 163 patients, 46 of whom (28.8%) were untreated for mCRPC. A higher number of ctDNA alterations, AR alterations, and amplifications of MYC and BRAF were associated with worse failure-free survival and/or OS. On multivariable analysis, MYC amplification remained significantly associated with OS. Prior therapy and serial profiling demonstrated the evolution of alterations in AR and other genes. Conclusions: ctDNA frequently was detected in this large cohort of “real-world” patients with mCRPC, and the alterations appeared to be similar to previously reported tumor tissue alterations. A higher number of alterations, and AR and MYC alterations, appear to compromise clinical outcomes, suggesting a role for immune checkpoint inhibitors and novel AR and BET inhibitors in selected patients.
AB - Background: Because cell-free DNA (cfDNA) analysis facilitates the noninvasive genomic profiling of metastatic castration-resistant prostate cancer (mCRPC), the authors evaluated the association between cfDNA alterations and outcomes and evolution with therapy. Methods: Patients with mCRPC underwent cfDNA genomic profiling using Guardant360, which examines major cancer-associated genes. Clinical factors, therapy information, failure-free survival, and overall survival (OS) were obtained for select patients. The association between genomic alterations and outcomes was investigated. Results: Of 514 men with mCRPC, 482 (94%) had ≥1 circulating tumor DNA (ctDNA) alteration. The most common recurrent somatic mutations were in TP53 (36%), androgen receptor (AR) (22%), adenomatous polyposis coli (APC) (10%), neurofibromin 1 (NF1) (9%), epidermal growth factor receptor (EGFR), catenin beta-1 (CTNNB1), and AT-rich interactive domain-containing protein 1A (ARID1A) (6% each); and BRCA1, BRCA2, and phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) (5% each) The most common genes with increased copy numbers were AR (30%), MYC (20%), and BRAF (18%). Clinical outcomes were available for 163 patients, 46 of whom (28.8%) were untreated for mCRPC. A higher number of ctDNA alterations, AR alterations, and amplifications of MYC and BRAF were associated with worse failure-free survival and/or OS. On multivariable analysis, MYC amplification remained significantly associated with OS. Prior therapy and serial profiling demonstrated the evolution of alterations in AR and other genes. Conclusions: ctDNA frequently was detected in this large cohort of “real-world” patients with mCRPC, and the alterations appeared to be similar to previously reported tumor tissue alterations. A higher number of alterations, and AR and MYC alterations, appear to compromise clinical outcomes, suggesting a role for immune checkpoint inhibitors and novel AR and BET inhibitors in selected patients.
KW - castration resistant
KW - circulating tumor DNA (ctDNA)
KW - failure-free survival
KW - genomic profiling
KW - metastatic
KW - prostate cancer
KW - survival
UR - http://www.scopus.com/inward/record.url?scp=85059666191&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059666191&partnerID=8YFLogxK
U2 - 10.1002/cncr.31959
DO - 10.1002/cncr.31959
M3 - Article
C2 - 30620391
AN - SCOPUS:85059666191
SN - 0008-543X
VL - 125
SP - 1459
EP - 1469
JO - Cancer
JF - Cancer
IS - 9
ER -